Prospective Observational Study of the Power PICC Family of Devices and Accessories

March 17, 2022 updated by: Becton, Dickinson and Company
Post-market, observational study to collect prospective data related to the safety and performance of the Power PICC family of devices and its accessories in a real-world setting.

Study Overview

Detailed Description

Single-arm, post-market, observational, prospective study to asses the safety and performance of the Power PICC Power PICC family of devices and its accessories in a real-world setting. The study will only enroll patients that need a Power PICC catheter as part of their medical care. Patients will be followed from insertion through removal, or up to 180 days (whichever comes first). Data collected will be gathered from the patient's medical chart.

Study Type

Observational

Enrollment (Actual)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Klagenfurt, Austria
        • Klinikum Klagenfurt
      • Vienna, Austria, A-1090
        • Medizinische Universität Wien
      • Leuven, Belgium, B-3000
        • University Hospitals KU Leuven
      • Olomouc, Czechia
        • Fakultní nemocnice Olomouc
      • Sønderborg, Denmark, 6400
        • Sygehus Soenderjylland, Sønderborg
      • Jena, Germany
        • Universitätsklinikum Jena
      • Napoli, Italy
        • Azienda Ospedaliera dei Colli - Monaldi
    • Piedmont
      • Alessandria, Piedmont, Italy, 15121
        • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo
      • Turin, Piedmont, Italy, 10126
        • A.O.U Città della Salute e della Scienza Torino, Ospedale Molinette
    • Piemonte
      • Ivrea, Piemonte, Italy, 10015
        • Ospedale Civile di Ivrea
    • Trentino
      • Bolzano, Trentino, Italy, 39100
        • Ospedale Centrale di Bolzano
      • Den Haag, Netherlands, 2545
        • Haga ziekenhuis
      • Girona, Spain
        • Hospital Universitari de Girona Dr Josep Trueta
      • Zürich, Switzerland, 8091
        • Institut für diagnostische und interventionelle Radiologie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Any patients who require a PICC device in a primary care facility.

Description

Inclusion Criteria:

  • Any patient, regardless of age or gender, for which the investigator has decided that one of the PowerPICC study devices for either short-or long-term venous access should be inserted as standard of care
  • Expected to be available for observation through the duration of PICC therapy (including outpatient therapy, if applicable)
  • Provision of signed and dated informed consent form (Note: Consent of guardian or parent may be required for patients under the age of 18 years; participant assent may be required as well.)

Exclusion Criteria:

  • Presence of any device-related infection, bacteremia, or septicemia is known or suspected
  • Body size is insufficient to accommodate the size of implanted device
  • Known or suspected to be allergic to materials contained in the device
  • History of irradiation of prospective insertion site
  • Previous episode(s) of venous thrombosis or vascular surgical procedures at the prospective placement site
  • Local tissue factors which would prevent proper device stabilization and/or access

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
All subjects
patients who require a PICC
insertion of a Peripherally Inserted Central Catheter (PICC)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of venous thrombosis
Time Frame: from insertion though removal or 180 days, whichever comes first
Incidence of venous thrombosis defined as any new occurrence of symptomatic venous thrombosis defined by thrombus presence by ultrasonography or other imaging
from insertion though removal or 180 days, whichever comes first
Percent PICC remain in place through therapy
Time Frame: from insertion though removal or 180 days, whichever comes first
Percent of PICCs that remain in place through the required therapy time period
from insertion though removal or 180 days, whichever comes first

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of phlebitis
Time Frame: from insertion though removal or 180 days, whichever comes first
Incidence of phlebitis where phlebitis is defined inflammation of the cannulated vessel identified by redness, swelling, warmth, tenderness, and/or cord formation
from insertion though removal or 180 days, whichever comes first
Incidence of extravasation
Time Frame: from insertion though removal or 180 days, whichever comes first
Incidence of extravasation where extravasation is defined as accidental infiltration of a vesicant or chemotherapeutic drug into the tissue around the catheter
from insertion though removal or 180 days, whichever comes first
Incidence of local infection
Time Frame: from insertion though removal or 180 days, whichever comes first
Incidence of local infection where local infection is defined as presence of pus at the exit site and/or culture confirmed site infection
from insertion though removal or 180 days, whichever comes first
Incidence of Catheter-related bloodstream infection
Time Frame: from insertion though removal or 180 days, whichever comes first
Incidence of Catheter-related bloodstream infection where Catheter-related bloodstream infection is defined as positive blood culture(s) with a microorganism not related to another source (e.g., UTI) OR positive blood culture(s) with microorganism matching catheter tip culture OR blood cultures from peripheral venous puncture and PICC positive with the same microorganism
from insertion though removal or 180 days, whichever comes first
Incidence of Accidental dislodgement
Time Frame: from insertion though removal or 180 days, whichever comes first
Incidence of Accidental dislodgement where Accidental dislodgement is defined as catheter accidentally dislodged the extent to which it requires replacement
from insertion though removal or 180 days, whichever comes first
Incidence of vessel laceration
Time Frame: during the insertion procedure
Incidence of vessel laceration where vessel laceration is defined as a tear in the tissue of the vessel
during the insertion procedure
Incidence of vessel perforation
Time Frame: during the insertion procedure
Incidence of vessel perforation where vessel perforation is defined as a hole formed in the vessel
during the insertion procedure
Percent of patent catheters
Time Frame: from insertion though removal or 180 days, whichever comes first
Percent of patent catheters defined as the number of functional catheters through therapy/total number of catheters
from insertion though removal or 180 days, whichever comes first
Percent of placement success in single insertion attempt
Time Frame: during the insertion procedure
Percent of placement success in single insertion attempt defined as placement success defined as single insertion attempt, proper tip location, and patent catheter
during the insertion procedure
Ease of insertion
Time Frame: during the insertion procedure
Ease of insertion determined by composite score of guidewire/stylet performance based on post-insertion survey (5 point Likert scale)
during the insertion procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 18, 2020

Primary Completion (Actual)

January 31, 2022

Study Completion (Actual)

March 1, 2022

Study Registration Dates

First Submitted

February 7, 2020

First Submitted That Met QC Criteria

February 7, 2020

First Posted (Actual)

February 11, 2020

Study Record Updates

Last Update Posted (Actual)

March 21, 2022

Last Update Submitted That Met QC Criteria

March 17, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • MDS-19PICCEU01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peripherally Inserted Central Catheter

Clinical Trials on Peripherally Inserted Central Catheter

3
Subscribe